Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/01/19
End: 05/20/20
Due: 05/20/21
Phase: N/A
Priority: Normal
Start: 11/23/21
End: 06/30/27
Due: 06/30/28
Phase: N/A
Priority: Normal
Start: 10/05/17
End: 01/08/19
Due: 01/08/20
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Intra-articular PVA Hydrogel in Knee Osteoarthritis | NCT04693104 | Rottapharm Biotech | user2@example.com | None | 2019-10-01 | 2020-05-20 | 2021-05-20 | - | - | 2025-07-14 |
| Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | NCT05205330 | Rottapharm Biotech | user2@example.com | None | 2021-11-23 | 2027-06-30 | 2028-06-30 | - | - | 2025-07-14 |
| A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis | NCT03163966 | Rottapharm Biotech | user2@example.com | None | 2017-10-05 | 2019-01-08 | 2020-01-08 | - | - | 2025-07-14 |